Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LSC-Exo Eye Drops for Dry Eye Syndrome
NCT06543667Phase 1Recruiting
- Sponsor
- Iran University of Medical Sciences
- Start
- Aug 2024
- Primary completion
- Jan 2026
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of limbal stem cell-derived exosomes in dry eye syndrome (DED), sponsored by Iran University of Medical Sciences. Primary endpoints: Change in Inflammatory and Pro-inflammatory cytokines at 12 weeks and Ocular Surface Disease Index at 12 weeks. Started Aug 2024; status: recruiting.
02
Drugs
limbal stem cell-derived exosomes
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT06543667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06543667.